Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Gane EJ, Rouzier R, Hassanein T, Stedman CA, Mazur W, Kupcova V, Le Pogam S, Eng S, Voulgari A, Morcos PN, Brennan BJ, Scalori A, Thommes J. Gane EJ, et al. Among authors: scalori a. Hepatol Int. 2016 May;10(3):478-87. doi: 10.1007/s12072-015-9699-9. Epub 2016 Feb 17. Hepatol Int. 2016. PMID: 26886127 Clinical Trial.
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, Perez-Gomez HR, Scalori A, Hooper GJ, Tavel JA, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, Nájera I, Eng S, Lim CY, Shulman NS, Yetzer ES. Feld JJ, et al. Among authors: scalori a. J Hepatol. 2015 Feb;62(2):294-302. doi: 10.1016/j.jhep.2014.09.013. Epub 2014 Sep 18. J Hepatol. 2015. PMID: 25239078 Clinical Trial.
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Wedemeyer H, Forns X, Hézode C, Lee SS, Scalori A, Voulgari A, Le Pogam S, Nájera I, Thommes JA. Wedemeyer H, et al. Among authors: scalori a. PLoS One. 2016 Jan 11;11(1):e0145409. doi: 10.1371/journal.pone.0145409. eCollection 2016. PLoS One. 2016. PMID: 26752189 Free PMC article. Clinical Trial.
HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients.
Roffi L, Ricci A, Ogliari C, Scalori A, Minola E, Colloredo G, Donada C, Ceriani R, Rinaldi G, Paris B, Fornaciari G, Morales R, Del Poggio P, Sangiovanni A, Buonocore M, Bellia V, Riboli P, Nava MC, Panizzuti F, Piperno A, Pozzi M, Pioltelli P, Mancia G. Roffi L, et al. Among authors: scalori a. J Hepatol. 1998 Nov;29(5):701-6. doi: 10.1016/s0168-8278(98)80249-3. J Hepatol. 1998. PMID: 9833906
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Peyrin-Biroulet L, et al. Among authors: scalori a. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798039 Free article. Clinical Trial.
Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype.
Roffi L, Redaelli A, Colloredo G, Minola E, Donada C, Picciotto A, Riboli P, Del Poggio P, Rinaldi G, Paris B, Fornaciari G, Giusti M, Marin R, Morales R, Sangiovanni A, Belloni G, Pozzi M, Poli G, Mascoli N, Corradi C, Pioltelli P, Scalori A, Mancia G. Roffi L, et al. Among authors: scalori a. Eur J Gastroenterol Hepatol. 2001 May;13(5):501-6. doi: 10.1097/00042737-200105000-00007. Eur J Gastroenterol Hepatol. 2001. PMID: 11396528 Review.
Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
Zhang W, Scalori A, Fuh F, McBride J, She G, Kierkus J, Korczowksi B, Li R, Abouhossein M, Kadva A, Park KT, Tang MT. Zhang W, et al. Among authors: scalori a. Inflamm Bowel Dis. 2022 Sep 1;28(9):1348-1356. doi: 10.1093/ibd/izab275. Inflamm Bowel Dis. 2022. PMID: 34849918 Free PMC article. Clinical Trial.
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J; HIBISCUS Study Group. Rubin DT, et al. Among authors: scalori a. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):17-27. doi: 10.1016/S2468-1253(21)00338-1. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798036 Clinical Trial.
24 results